Decline in pneumococcal meningitis after the introduction of the heptavalent-pneumococcal conjugate vaccine in northern France

Archives of Disease in Childhood

Volumn 92, Issue 11, 2007, Pages 1009-1012

  Dubos, F ^a,b   Marechal, I ^b   Husson, M O ^b   Courouble, C ^c   Aurel, M ^b   Martinot, A ^b  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b UNIV LILLE   (France)

^c Department of Addictology Le Square   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS VACCINE;

ARTICLE; BACTERIAL MENINGITIS; CHILD; CLINICAL TRIAL; COHORT ANALYSIS; FEMALE; FRANCE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; INCIDENCE; INFANT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE;

EID: 35748967840     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.2007.119891     Document Type: Article

References (33)

1. Swartz MN. Bacterial meningitis - a view of the past 90 years. N Engl J Med 2004;351:1826-8.
2. Jefferson T, Ferroni E, Curtale F, et al. Streptococcus pneumoniae in western Europe: serotype distribution and incidence in children less than 2 years old. Lancet Infect Dis 2006;6:405-10.
3. Bingen E, Levy C, De la Rocque F, et al. Bacterial meningitis in children: a French prospective study. Clin Infect Dis 2005;41:1059-63.
4. Perrocheau A, De Benoist AC, Six C, et al. Epidemiology of bacterial meningitis in France in 1999. Ann Med Interne 2002;153:311-17.
5. Arditi M, Mason EO, Bradley JS, et al. Three-year multicenter surveillance of pneumococcal meningitis in children: clinical characteristics, and outcome related to penicillin susceptibility and dexamethasone use. Pediatrics 1998;102:1087-97.
6. Bohr VA, Rasmussen N. Neurological sequelae and fatality as prognostic measures in 875 cases of bacterial meningitis. Dan Med Bull 1988;35:92-5.
7. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000;19:187-95.
8. Eskola J. Immunogenicity of pneumococcal conjugate vaccines. Pediatr Infect Dis 1 2000;19:388-93.
9. Feikin DR, Klugman KP. Historical changes in pneumococcal serogroup distribution: implications for the era of pneumococcal conjugate vaccines. Clim Infect Dis 2002;35:547-55.
10. Le Conseil Supérieur d'Hygiène Publique de France. Avis du Conseil Supérieur d'Hygiène Publique de France du 8 mars 2002, relatif à la vaccination par le vaccin pneumococcique heptavalent conjugué (Prevenar), www.sante.gouv.fr/ htm/dossiers/cshpf/ a_mt_080302_pneumo_conjugue.pdf (accessed 16 August 2007).
11. Cohen R, Gaudelus J, Peixoto O. Antipneumococcal conjugate vaccine: estimation of the target population. Survey among 1739 mothers. Méd Enfance 2005;25:237-42.
12. Eskola J, Kilpi T, Palmu A, et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 2001;344:403-9.
13. Black SB, Shinefield HR, Ling S, et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J 2002;21:810-15.
14. Whitney CG, Parley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003;348:1737-46.
15. Kellner JD, Church DL, MacDonald J, et al. Progress in the prevention of pneumococcal infection. CMAJ 2005;173:1149-51.
16. Roche P, Krause V, Cook H, et al. Invasive pneumococcal disease in Australia, 2005. Commun Dis Intell 2007;31:86-100.
17. Niqrovic LE, Kuppermann N, Malley R. Development and validation of a multivariable predictive model to distinguish bacterial from aseptic meningitis in children in the post-Haemophilus influenzae era. Pediatrics 2002;110:712-19.
18. Greenlee JE. Approach to diagnosis of meningitis. Infect Dis Clin North Am 1990;4:583-98.
19. Bonsu BK, Harper MB. Differentiating acute bacterial meningitis from acute viral meningitis among children with cerebrospinal fluid pleocytosis: a multivariable regression model. Pediatr Infect Dis J 2004;23:511-17.
20. Chao A, Tsay PK, Lin SH, et al. The applications of capture-recapture models to epidemiological data. Star Med 2001;20:3123-57.
21. Hsu K, Pelton S, Karumuri S, et al. Population-based surveillance for childhood invasive pneumococcal disease in the era of conjugate vaccine. Pediatr Infect Dis J 2005;24:17-23.
22. Black S, Shinefield H, Baxter R, et al. Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente. Pediatr Infect Dis J 2004;23:485-9.
23. Poehling KA, Talbot TR, Griffin MR, et al. Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine. JAMA 2006;295:1608-74.
24. Centers for Disease Control and Prevention (CDC). Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease-United States, 1998-2003. MMWR Morb Mortal Wkly Rep 2005;54:893-7.
25. Doit C, Loukil C, Geslin P, et al. Phenotypic and genetic diversity of invasive pneumococcal isolates recovered from French children. J Clin Microbiol 2002;40:2994-8.
26. Perrocheau A, Doyle A, Bernillon P, et al. Estimation du nombre total de méningites à pneumocoque de l'enfant, par la méthode capture-recapture à 3 sources, France, 2001-2002. Bull Epidemiol Hebd 2006;2-3:16-18.
27. Lepoutre A, Georges S, Varon E, et al. Evolution of pneumococcal invasive disease incidence, France, 2005. Bull Epidemiol Hebd 2007;5:37-9.
28. Le Conseil Supérieur d'Hygiène Publique de France. Avis du Conseil Supérieur d'Hygiène Publique de France du 19 mai 2006, relatif à la vaccination par le vaccin anti-pneumococcique conjugué chez les enfants de moins de deux ans et les enfants de deux à cinq ans.www.sante.gouv.fr/htm/dossiers/cshpf/ a_mt_190506_pneumo_enf. pdf (accessed March 12, 2007).
29. Cohen R, Levy C, De la Rocque F, et al. French national survey of nasopharyngeal carriage of Streptococcus pneumoniae among infants and toddlers suffering from acute otitis media. Pediatr Infect Dis J 2006;25:1001-7.
30. Huang SS, Platt R, Rifas-Shiman SL, et al. Post-PCV7 changes in colonizing pneumococcal serotypes in 16 Massachusetts communities, 2001 and 2004. Pediatrics 2005;116:e408-13.
31. Kyaw MH, Lynfield R, Schaffner W, et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med 2006;354:1455-63.
32. Kaplan SL, Mason EO, WaId ER, et al. Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics 2004;113:443-9.
33. Hanage WP, Huang SS, Lipsitch M, et al. Diversity and antibiotic resistance among nonvaccine serotypes of Streptococcus pneumoniae carriage isolates in the post-heptavalent conjugate vaccine era. J Infect Dis 2007;195:347-52.